($) USD (Default)
  • ($) AUD
  • (€) EUR
  • ($) CAD
  • ($) NZD
  • (£) GBP

Thymosin Alpha-1 Peptides

Buy Thymosin Alpha-1 Peptides Online From Direct Sarms Hungary

Known for its immune-modulating properties, Thymosin Alpha-1 acts as a powerful stimulant, facilitating the activation and maturation of T cells. This peptide plays a crucial role in regulating immune responses, supporting the body’s defense mechanisms against infections, viruses, and chronic diseases.

Studies suggest by boosting cellular immunity, Thymosin Alpha-1 research peptide has garnered attention among Hungary researchers and medical professionals worldwide. It has been the subject of numerous studies exploring its impact on various conditions, including viral infections, autoimmune disorders, and cancer.

What is Thymosin Alpha-1?

Thymosin Alpha-1, also known as Thymalfasin or Ta1, is a 28 amino acid peptide which acts as a natural regulator of immune function, originating from the thymus gland. This peptide plays a crucial role in the adaptive immune response by affecting immune cells like dendritic and plasmacytoid dendritic cells. Hungary Clinical studies have shown its efficacy in treating conditions such as chronic hepatitis B, chronic hepatitis C, hepatocellular carcinoma, liver cancer, breast cancer, lung cancer, HIV, sepsis, cytomegalovirus and tuberculosis.

The peptide’s actions include restoring immune responses, regulating cytokine production, and modulating receptor expression. It is used in immunotherapy to boost the body’s defense against infections and malignancies. Ta-1 has been proven safe and effective in various Hungary clinical trials with minimal side effects.

Approved by the FDA, Thymosin Alpha-1 is available for use alone or in combination therapies. Ongoing research explores its potential in treating respiratory disorders like cystic fibrosis and chronic inflammatory conditions. Bulk orders must meet strict purity standards and should be stored at room temperature for stability.

How Does Thymosin Alpha-1 Work?

Thymosin Alpha-1 enhances the immune response by modulating various immune system components. It upregulates dendritic and plasmacytoid dendritic cells, promoting their maturation and function, which improves antigen presentation—a crucial step in T-cell activation and adaptive immunity.

This peptide also influences cytokine production, boosting interferon-alpha and other cytokines, thereby enhancing the body’s defense against viral infections and tumors. Additionally, Ta1 improves immune cell receptor expression, aiding in the recognition and response to pathogens.

Due to its immune-strengthening properties, Thymosin Alpha-1 is valuable in immunotherapy for chronic infections and malignancies. Its low toxicity and minimal side effects make it suitable for both monotherapy and combination therapy. Healthcare practitioners and researchers may seek to buy Thymosin Alpha-1 for Hungary clinical and investigational purposes.

Exploring Ta-1’s mechanisms and applications could lead to new therapeutic strategies for managing respiratory disorders, chronic inflammatory diseases, and enhancing cancer treatments.

Thymosin Alpha-1 Specifications

PubChem CID: 16130571

Molecular Formula: C129H215N33O55

Molecular Weight: 3108.3 g/mol

Sequence: Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn-OH

Thymosin Alpha-1 StructureSource: PubChem

View our Thymosin Alpha-1 High-Performance Liquid Chromatography (HPLC) Certificate here.

What are the suggested research benefits of Thymosin Alpha-1 Peptides?

  • Enhanced Immune Response: Increases the production and activity of dendritic cells and plasmacytoid dendritic cells, facilitating T-cell activation.
  • Improved Antigen Presentation: Promotes efficient antigen presentation, critical for initiating and sustaining a robust adaptive immune response.
  • Cytokine Modulation: Enhances cytokine production, including interferon alpha, vital for combating viral infections and tumour progression.
  • Receptor Expression Regulation: Modulates receptor expression on immune cells, leading to better recognition and response to pathogens.
  • Combats Fungal Infections: This peptide shows promise in fighting fungal infections, especially from Candida species. By upregulating dendritic cells and boosting cytokine production, Ta-1 strengthens the body’s defenses against fungal invaders.
  • Reduced Toxicity and Adverse Effects: Demonstrated low toxicity and minimal adverse effects, making it suitable for various therapeutic protocols.
  • Cancer Therapy Support: Hungary Research shows promise in augmenting the efficacy of cancer treatments, particularly in breast and lung cancer.
  • Infectious Disease Management: Effective in improving immune function in chronic infections such as HIV, hepatitis B, and tuberculosis.
  • Potential in Respiratory Disorders: Emerging research indicates benefits in treating cystic fibrosis and other chronic inflammatory respiratory conditions.
  • Blood Pressure Regulation: By inhibiting the angiotensin-converting enzyme (ACE), it helps manage blood pressure. Additionally, its capacity to modulate the immune response and reduce inflammation can further stabilize blood pressure, particularly in patients with chronic inflammatory conditions.
  • Versatile Application: Suitable for both monotherapy and combination therapy, broadening its therapeutic use cases.
  • Nerve Growth Promotion: Hungary Research indicates potential benefits in promoting nerve growth, which could have implications in treating neurodegenerative diseases and enhancing nervous system repair.
  • Safe Long-term Use: Safe for prolonged use in clinical settings, supported by multiple clinical trials and FDA approval.

What Thymosin Alpha-1 products are available?

Thymosin Alpha-1 and LL-37 Peptide Stack

Thymosin Alpha-1 and LL-37Buy Thymosin Alpha-1 and LL-37 (CAP-18) Peptide Stack for clinical research from Hungary Direct Sarms. The stack consists of 1 x 10mg vial of Thymosin Alpha-1 (Ta1) and 1 x 5mg vial of LL-37 (CAP-18).

The combination of Thymosin Alpha-1 and LL-37 peptides offers a powerful strategy for boosting immunotherapy. Ta-1 is known for its immune-modulating effects, including increased T-cell activation, better antigen presentation, and cytokine production, which strengthen the body’s immune responses.

LL-37 adds broad-spectrum antimicrobial activity, promotes wound healing, and modulates inflammation. Together, these peptides improve the immune system’s ability to fight infections, reduce inflammation, and support tissue repair, making it a promising approach for managing complex immune conditions and enhancing overall health.

Thymosin Alpha-1 Nasal Spray

Thymosin alpha-1 Nasal SprayBuy Thymosin Alpha-1 nasal sprays (Ta1) Peptides for research from Direct Sarms Hungary. Available in 15ml (5mg Ta1) and 30ml (10mg Ta1) spray bottles.

Thymosin Alpha-1 nasal formulation is an emerging method to improve the administration and efficacy of Ta-1. Using a nasal route, this approach aims for direct and efficient delivery to the immune system, potentially enhancing the peptide’s bioavailability and therapeutic effects.

It could be especially beneficial for patients with chronic respiratory conditions, allowing targeted treatment of nasal and lung pathologies. As research progresses, Thymosin Alpha-1 nasal could become a key addition to immunotherapeutic strategies, offering a convenient and effective alternative to traditional methods.

Frequently Asked Questions (FAQ’s) about Thymosin Alpha-1 Peptides

Thymosin Alpha-1 FAQs

What do I use to reconstitute Thymosin Alpha-1 (Ta-1)?

To reconstitute Thymosin Alpha-1 (Ta-1), use bacteriostatic or sterile water for injection, available from Direct SARMs Hungary. Clean the vial’s rubber stopper with an alcohol swab. Inject the appropriate amount of water into the vial slowly to avoid foaming. Gently swirl the vial until the powder dissolves completely; do not shake as this can damage the peptide. Store reconstituted Ta-1 in a refrigerator at 2-8°C and do not freeze. Use within the recommended time frame, usually 14 days.

Is Thymosin Alpha-1 legal?

Yes, Ta-1 is legal and has been approved for clinical use in various countries. In the United States, the Food and Drug Administration (FDA) has granted approval for its use in certain therapeutic contexts. Similarly, the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom permits the use of Thymosin Alpha-1 under prescribed conditions. In Australia, the Therapeutic Goods Administration (TGA) also recognizes the peptide, allowing it for specific medical applications.

What conditions can Thymosin Alpha-1 treat?

Ta-1 has been approved for the treatment of hepatitis B and C, liver diseases like hepatocellular carcinoma, breast and lung cancer, HIV infection, sepsis, and tuberculosis. Emerging research also indicates potential benefits in managing cystic fibrosis and chronic inflammatory respiratory conditions.

It is important to note that our peptides are not for human use. Therefore, you can only buy Thymosin Alpha-1 peptides on the Direct Sarms website are for scientific research purposes only and not for human consumption.

What ongoing research is being conducted on Thymosin Alpha-1?

Research is ongoing to explore additional therapeutic applications of Ta-1, including its potential in respiratory disorders, acquired immune response syndrome, influenza, chronic inflammatory diseases, and further enhancements in cancer therapies.

Can Thymosin Alpha-1 be used alongside other treatments?

Thymosin Alpha-1 is versatile and can be used both as a monotherapy and in combination protocols to enhance the efficacy of other treatments, particularly in cancer therapy and chronic infections.

Does Thymosin Alpha-1 Have Any Side Effects?

Thymosin Alpha-1 is generally well-tolerated with minimal adverse effects. Clinical studies indicate that the most common side effects are mild and transient, including injection site reactions such as redness, swelling, or pain. Rarely, users may experience flu-like symptoms, fatigue, or gastrointestinal disturbances.

Importantly, Thymosin Alpha-1 has a low toxicity profile and does not exhibit significant immunosuppressive effects. Healthcare providers should monitor patients for any adverse reactions, particularly when used in combination with other therapies. Overall, its safety profile supports its use in long-term treatment protocols.

Where is the best place to buy Thymosin Alpha-1?

The best place to buy Thymosin Alpha-1 for research is from Direct SARMs Hungary. Their products are rigorously tested and meet the highest standards of purity and quality, ensuring optimal results for scientific investigations. So, it is important to only purchase from reputable and authorised sources to ensure safe and effective use.

Further Reading

Discover more by exploring our latest blog articles focused on Thymosin Alpha-1 peptides.

Buy Thymosin Alpha-1 Peptides Today!

Researchers interested in expanding their studies on immune modulation and peptide therapy should consider the option to buy Ta-1. Available in multiple forms, including nasal sprays and subcutaneous injections such as 10mg Ta1 peptide vial and Thymosin Alpha-1 Pre-mixed Pen 10mg. This peptide is known for its effectiveness in boosting immune responses, making it valuable for research on chronic infections, cancer therapy, and autoimmune diseases.

At Direct Sarms, we offer high-quality Thymosin Alpha-1 in various formats to meet different experimental needs, ensuring reliability and consistency. When you buy Thymosin Alpha-1 from Direct Sarms, you are assured of high purity standards and excellent customer support, making it a great choice for advancing your research.

Scientific References

[1] K.M.Malinda, G.S.Sidhu, K.K.Banaudha, et al (1998) Thymosin alpha 1 stimulates endothelial cell migration, angiogenesis, and wound healing – Journal of Immunology, 1998 Jan 15, Volume 160 (Issue 2), Pages 1001-6.

[2] J.Wu, L.Zhou, J.Liu, et al (2013) The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial – Critical Care, 2013, 17 (1): Article number R8.

[3] F.Pei, X.Guan, and J.Wu (2018) Thymosin alpha 1 treatment for patients with sepsis – Expert Opinion on Biological Therapy, 2018 Jul, Volume 18 (Issue supplement 1), Pages 71-76.

[4] L.Romani, F.Bistoni, R.Gaziano, et al (2004) Thymosin alpha 1 activates dendritic cells for antifungal Th1 resistance through toll-like receptor signaling – Blood, 2004 Jun 1, Volume 103 (Issue 11), Pages 4232-9.

[5] L.Romani, F.Bistoni, C.Montagnoli, et al (2007) Thymosin alpha1: an endogenous regulator of inflammation, immunity, and tolerance – Annals of the New York Academy of Sciences, 2007 September, Volume 1112 (Issue 1), Pages 326-38.

[6] A.Dominari, D.Hathaway III, K.Pandav, et al (2020) Thymosin alpha 1: A comprehensive review of the literature – World Journal of Virology, 2020 Dec 15, Volume 9 (Issue 5), Pages 67–78.

[7] C.Matteucci, S.Grelli, E.Balestrieri, et al (2017) Thymosin alpha 1 and HIV-1: recent advances and future perspectives – Future Microbiology, 2017 Feb, Volume 12, Pages 141-155.

[8] C.Matteucci, A.Minutolo, M.Pollicita, et al (2015) Thymosin α 1 potentiates the release by CD8(+) cells of soluble factors able to inhibit HIV-1 and human T lymphotropic virus 1 infection in vitro – Expert Opinion on Biological Therapy, 2015, Volume 15, Issue Supplement 1, Pages 83-100.

[9] J. Kharazmi-Khorassani, A. Asoodeh, and H. Tanzadehpanah (2019) Antioxidant and angiotensin-converting enzyme (ACE) inhibitory activity of thymosin alpha-1 (Thα1) peptide – Bioorganic Chemistry, Volume 87, June 2019, Pages 743-752.

[10] R.Danielli, E.Fonsatti, L.Calabrò, et al (2012) Thymosin α1 in melanoma: from the clinical trial setting to the daily practice and beyond -Annals of the New York Academy of Sciences, Volume 1270, Issue 1, Thymosins in Health and Disease II, October 2012, Pages 8-12.

[11] Y.Guo, H.Chang, J.Li, et al (2015) Thymosin alpha 1 suppresses proliferation and induces apoptosis in breast cancer cells through PTEN-mediated inhibition of PI3K/Akt/mTOR signaling pathway – Apoptosis, Published: 23 May 2015, Volume 20, pages 1109–1121.


DISCLAIMER: These products are intended solely as a research chemical only. This classification allows for their use only for research development and laboratory studies. The information available on our Hungary Direct Sarms website is provided for educational purposes only. These products are not for human or animal use or consumption in any manner. Handling of these products should be limited to suitably qualified professionals. They are not to be classified as a drug, food, cosmetic, or medicinal product and must not be mislabelled or used as such.